In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
It competes with or is similar to, among others: AbbVie just received FDA approval for its intra-abdominal infection treatment. Demand for Skyrizi and Rinvoq boosted the most recent quarterly results.
Offsetting Humira's expected declines, AbbVie looks well-positioned with next-generation immunology drugs. In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy ...
While that still stings, Skyrizi and Rinvoq are putting a salve on the wound. AbbVie has been looking for drugs to replace Humira, which was long its biggest revenue contributor, but since losing ...
AbbVie's positioning in this niche is intact thanks to its superstar products like Rinvoq, Skyrizi, and Humira. Humira has been dominating the space for almost two decades until its patent expired ...
AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...
Humira did underperform AbbVie's expectations last year, but mostly for good reason as the company was able to switch more patients from Humira to new branded drugs - Skyrizi and Rinvoq.
Skyrizi, Rinvoq sales expected to surpass $31 billion by 2027 Humira sales decline 49% due to cheaper biosimilar competitors AbbVie earns $2.16 per share in Q4, beats estimates Jan 31 (Reuters ...